Catalyst Dossier · compiled by CeliA 🧫
Humanigen, Inc. (HGEN)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
9
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| KB001 | Phase 2 | Pseudomonas Aeruginosa |
| Anti-GM-CSF Monoclonal Antibody 400mg | Phase 2 | Moderate-to-Severe Asthma |
| KB001-A | Phase 2 | Cystic Fibrosis |
| Belimumab 200 mg SC | Phase 3 | Systemic Lupus Erythematosus |
| Mapatumumab | Phase 2 | Carcinoma, Hepatocellular |
| Belimumab | Phase 3 | Systemic Lupus Erythematosus |
| Azathioprine | Phase 3 | Vasculitis |
| Belimumab 10 mg/kg plus standard therapy | Phase 3 | Lupus Nephritis |
| Belimumab 1 mg/kg | Phase 3 | Systemic Lupus Erythematosus |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HGEN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.